Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This trial will assess the sustained virologic response to treatment with peginterferon
alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected
patients with hepatitis C virus (HCV) genotype 1 or 4 coinfection and persistent transaminase
elevations. These patients will have been nonresponders to previous regimens with
peginterferon alfa and ribavirin therapy at a dosage of 800-1200 mg/d.
Phase:
Phase 4
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Collaborators:
Fundacio Lluita Contra la SIDA Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia